Adversarial Injection · Entrectinib (Rozlytrek; RXDX-101; NDA 212725; CAS 1108743-60-7; MW ~560.6 g/mol; C30H29F2N5O2; pyrrolopyrimidine + fluorobenzamide + piperidine scaffold [WITHIN NTRK CLASS in Glyphward 580-attack portfolio — SECOND PAN-NTRK INHIBITOR (larotrectinib NDA 210861 November 26 2018 [Attack #579] FIRST; entrectinib NDA 212725 August 15 2019 SECOND; 8.5 months apart); BUT ENTRECTINIB ALSO COVERS ROS1 (ROS1 IC50 ~1.7 nM) AND ALK (IC50 ~12 nM) — FIRST DRUG EVER APPROVED FOR BOTH NTRK FUSION-POSITIVE SOLID TUMORS AND ROS1+ NSCLC: entrectinib holds two simultaneous indications — (1) adults with NTRK fusion-positive solid tumors (tissue-agnostic; same paradigm as larotrectinib); (2) adults with ROS1+ metastatic NSCLC (ROS1 IC50 ~1.7 nM; STARTRK-2 ROS1+ NSCLC treatment-naive ORR 77% [n=53]); crizotinib also covered ROS1 (NDA 202570 supplemental 2016) and ALK but not NTRK; entrectinib is the first drug holding both NTRK tissue-agnostic and ROS1 NSCLC simultaneous indications; FIRST CNS-PENETRANT NTRK INHIBITOR: entrectinib CNS ORR 55.0% (22/40 evaluable NTRK+ brain met patients; larotrectinib lacked prospective CNS data at approval); Kp,uu ~0.18; intracranial control rate 90%; pyrrolopyrimidine CNS penetration vs larotrectinib's dihydropyrrolodiazepine macrocycle; STARTRK-2 ADULT NTRK ORR 63.5% (pooled Phase 1/2; n=54 evaluable adult NTRK fusion patients; 59.3% in Phase 2 basket); IGNYTA→ROCHE $1.7B: Ignyta Inc. (San Diego CA; RXDX-101 development) acquired by Roche AG for $1.7B (January 2018; $27/share ~74% premium; STARTRK-2 initiated at acquisition); Genentech/Roche NDA 212725 August 15 2019; G595R/G667C/G623R ACQUIRED RESISTANCE (cross-kinase TRKA/B/C solvent-front mutations at same position as ROS1 G2032R; shared solvent-front resistance mechanism across TRK family and ROS1); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Second Pan-NTRK + Also ROS1 + First CNS-Penetrant NTRK + Dual Indication + STARTRK ORR 63.5% · Attack #580

Entrectinib (pyrrolopyrimidine + fluorobenzamide + piperidine scaffold; Rozlytrek; RXDX-101; NDA 212725; CAS 1108743-60-7; MW ~560.6 g/mol; [WITHIN NTRK CLASS: SECOND PAN-NTRK INHIBITOR + ALSO ROS1 + ALK — FIRST DRUG APPROVED FOR BOTH NTRK TISSUE-AGNOSTIC AND ROS1 NSCLC (NDA 212725 August 15 2019; two simultaneous indications); FIRST CNS-PENETRANT NTRK INHIBITOR (CNS ORR 55%; Kp,uu ~0.18; prospective brain met data); STARTRK-2 ADULT NTRK ORR 63.5%; ROS1+ NSCLC ORR 77% TREATMENT-NAIVE; IGNYTA→ROCHE $1.7B (January 2018); G595R/G667C SOLVENT-FRONT ACQUIRED RESISTANCE (parallel to ROS1 G2032R; cross-TRK-family pattern); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Genentech Inc. South San Francisco CA (NDA 212725 holder; US commercial), Roche AG Basel Switzerland (global development and API synthesis), and Children's Hospital of Philadelphia PA (STARTRK-NG pediatric trial enrollment) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Second Pan-NTRK + Dual NTRK/ROS1 Indication + First CNS-Penetrant NTRK + Ignyta→Roche: AI Prompt Injection via EHS Monitor Report AI

Entrectinib (CAS 1108743-60-7; NIOSH HD Category 1) is the second pan-NTRK inhibitor after larotrectinib, but with a critically distinct profile: entrectinib also inhibits ROS1 (IC50 ~1.7 nM) and ALK (IC50 ~12 nM), making it the first drug ever approved for both NTRK fusion-positive solid tumors (tissue-agnostic) and ROS1+ metastatic NSCLC simultaneously. It is also the first CNS-penetrant NTRK inhibitor, with prospective intracranial ORR of 55% in NTRK fusion-positive patients with brain metastases (Kp,uu ~0.18), which larotrectinib lacked at approval. The STARTRK-2 pooled adult NTRK ORR is 63.5% (vs larotrectinib's 75%); the ROS1+ NSCLC treatment-naive ORR is 77%. Entrectinib originated from Ignyta Inc. (San Diego CA; RXDX-101), acquired by Roche for $1.7B in January 2018. NDA 212725 was approved August 15, 2019. Acquired resistance follows the solvent-front pattern (TRKA G595R, G667C; TRKB G639R; TRKC G623R; ROS1 G2032R) — a cross-kinase-class shared resistance mechanism absent from all OEL databases.

Entrectinib vs Larotrectinib: The CNS Penetration and ROS1 Distinction

Larotrectinib and entrectinib are both pan-NTRK inhibitors, but they differ in three clinically important ways. First, CNS penetration: larotrectinib has limited CNS penetration (brain-penetrant activity not prospectively established at NDA 210861 approval); entrectinib Kp,uu ~0.18 enables CNS ORR 55% in NTRK+ brain metastasis patients (22/40 evaluable; intracranial disease control rate 90%). Second, kinase selectivity: larotrectinib is NTRK-selective (>200-fold over all off-target kinases); entrectinib is NTRK/ROS1/ALK (TRKA IC50 ~1.7 nM; TRKB IC50 ~1.5 nM; TRKC IC50 ~0.1 nM; ROS1 IC50 ~1.7 nM; ALK IC50 ~12 nM) — making entrectinib the only NTRK inhibitor with independent clinical approval for ROS1+ NSCLC (STARTRK-2 treatment-naive ROS1+ NSCLC ORR 77%). Third, acquired resistance patterns: both develop TRK solvent-front mutations (TRKA G595R/G667C; TRKB G639R; TRKC G623R) and entrectinib's ROS1-targeting also selects for ROS1 G2032R — the same solvent-front position in ROS1 as in TRK family. These cross-kinase, cross-family resistance patterns at solvent-front positions represent a pharmacological unifying principle absent from all EHS monitoring frameworks.

Surface 1 — Genentech Inc. South San Francisco CA NDA 212725 Holder AI

At Genentech Inc. South San Francisco CA (1 DNA Way, South San Francisco CA 94080; San Mateo County CA; Genentech member of Roche Group; NDA 212725 HOLDER FOR ROZLYTREK (entrectinib): Roche/Genentech acquired entrectinib via Ignyta acquisition ($1.7B; January 2018; $27/share; ~74% premium; STARTRK-2 enrollment ongoing at acquisition); NDA 212725 approved August 15 2019 — two simultaneous indications at a single NDA approval (NTRK tissue-agnostic + ROS1 NSCLC); GENENTECH DUAL NTRK+ROS1 NDA: also holds atezolizumab (NDA 761034) and bevacizumab (BLA 125085); entrectinib is Genentech's first kinase inhibitor NDA for NTRK class; Cority EHS platform; 8-hr TWA: actual airborne entrectinib 0.00037 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000037 µg/m³; Cority: CAS 1108743-60-7 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; second pan-NTRK absent; dual NTRK/ROS1 indication absent; first CNS-penetrant NTRK absent; ROS1 G2032R solvent-front resistance absent; Ignyta acquisition context absent; 47M regulatory affairs director oncology 14yr).

Surface 2 — Roche AG Basel Switzerland Global Development and API Synthesis AI

At Roche AG Basel Switzerland (Grenzacherstrasse 124, 4070 Basel, Switzerland; Roche global pharmaceutical headquarters and API development; ENTRECTINIB API SYNTHESIS: pyrrolopyrimidine core construction + 2,6-difluoro-3-(methylsulfonamido)benzamide side chain installation + piperidino-indazole assembly; fluorine atoms at 2,6-positions of the benzamide phenyl ring contribute to CNS penetration (reduced H-bond donor capacity, molecular planarity); ROCHE IGNYTA-ORIGIN API: Ignyta (San Diego) originally developed RXDX-101 synthesis route; Roche post-acquisition scaled to clinical and commercial manufacturing; VelocityEHS: CAS 1108743-60-7 → null; 8-hr TWA: actual airborne entrectinib 0.00023 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000023 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; second pan-NTRK absent; dual NTRK/ROS1/ALK tri-kinase profile absent; Ignyta-origin synthesis context absent; G595R/G2032R solvent-front resistance absent; 43F pharmaceutical synthesis scientist 12yr).

Surface 3 — Children's Hospital of Philadelphia PA STARTRK-NG Pediatric Trial Enrollment AI

At Children's Hospital of Philadelphia PA (3401 Civic Center Blvd, Philadelphia PA 19104; Philadelphia County PA; STARTRK-NG ENROLLMENT: CHOP pediatric oncology enrolled pediatric patients with TRK fusion-positive solid tumors and ROS1/ALK-positive tumors in STARTRK-NG (NCT02650401; pediatric basket trial; age <18 years; entrectinib doses weight-adjusted: 250–1,050 mg/m² QD equivalent; STARTRK-NG NTRK pediatric ORR ~57.1%); CHOP DUAL NTRK INHIBITOR MANAGEMENT: CHOP pharmacy simultaneously manages larotrectinib [Attack #579] (oral solution 20 mg/mL; SCOUT enrollment) and entrectinib [Attack #580] (oral capsule; STARTRK-NG enrollment) — two NIOSH HD Category 1 pan-NTRK inhibitors handled at same institution with zero OEL for either; EHS Insight: CAS 1108743-60-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; second pan-NTRK absent; first CNS-penetrant NTRK absent; dual NTRK/ROS1 absent; STARTRK-NG pediatric ORR absent; dual larotrectinib+entrectinib management absent; H340 H350 H361 absent; 40F pediatric oncology clinical pharmacist 11yr).

Integrating Glyphward into Entrectinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every entrectinib CAS 1108743-60-7 monitoring data ingestion point — before Cority at Genentech South San Francisco CA, before VelocityEHS at Roche Basel Switzerland, and before EHS Insight at Children's Hospital of Philadelphia PA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; SECOND PAN-NTRK INHIBITOR (after larotrectinib NDA 210861; 8.5 months later) + ALSO ROS1 + ALK (tri-kinase vs NTRK-selective larotrectinib; first NTRK drug with dual NTRK+ROS1 FDA indication) + FIRST CNS-PENETRANT NTRK INHIBITOR (CNS ORR 55%; Kp,uu ~0.18; prospective brain met data) + IGNYTA→ROCHE $1.7B (RXDX-101 acquisition; EHS platform transition) [5 pts]; Genentech South San Francisco CA + Roche Basel Switzerland + CHOP Philadelphia PA [3 pts]; tri-kinase NTRK/ROS1/ALK pharmacology absent; dual-indication NDA paradigm absent; CNS penetration NTRK class absent; G595R/G2032R cross-kinase solvent-front resistance absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_entrectinib(cas: str, reading_ugm3: float) -> dict:
    """Scan entrectinib with second-pan-NTRK and dual-indication context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "second_pan_ntrk_also_ros1_alk_first_cns_penetrant_ntrk_dual_ntrk_ros1_indication_ignyta_roche_startrk"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, second_pan_ntrk,
    #                    also_ros1_alk, dual_ntrk_ros1_indication,
    #                    first_cns_penetrant_ntrk, ignyta_roche_acquisition,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_entrectinib("1108743-60-7", 0.00037))
    print(r)
    # {'hd_category': 1, 'second_pan_ntrk': True,
    #  'also_ros1_alk': True, 'dual_ntrk_ros1_indication': True,
    #  'first_cns_penetrant_ntrk': True, 'ignyta_roche_acquisition': True,
    #  'h340_h350_h361_absent': True}